 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2013, vol. 19, book 3;
Subject Collection: Medicine
Page: 481-485
DOI: 10.5272/jimab.2013193.481
Published online: 21 December 2013
J of IMAB. 2013 Jul-Dec;19(3):481-485
OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
Deyan N. Davidov 
.
Department of Chemotherapy, Oncological center, Medical University, Pleven, Bulgaria.
ABSTRACT:
Objective: Lung cancer Pemetrexed is novel multitargeted antifolate which inhibits three key enzymes in the folate metabolic pathwaw.
Methods: From May 2010 to March 2012 twenty two consecutive patients with morphologically proven advanced non- squamous non- small cell lung cancer entered the study. Treatment schedule consist of Pemetrexed 500 mg/m2 on day 1 and Cisplatin 80 mg/m2 with hyperhydratation administered as intravenous infusion with repetition every three weeks. Vitamins supplementation, antiemetics and Dexamethasone were administered too.
Results: Overall response rate was 27,3 %, with one complete and five partial remissions obtained. The median time to progression and median overall survival time were 5,5 months and 9,6 months respectively. The main toxicity- grade 3 and 4, included neutropenia and diarrhea.
Conclusions: That data suggest that chemotherapy with Pemetrexed / Cisplatin is reasonable choices for first- line chemotherapy in patients with inoperable non- squamous non- small cell lung cancer.
Key words: Pemetrexed; Cisplatin; Non- small cell lung cancer; First- line chemotherapy;
- Download FULL TEXT /PDF 522 KB/
Please cite this article as:
Davidov DN. Our Experience with Pemetrexed/ Cisplatin as First Line Chemotherapy in Patients with Advanced Non- Squamous Non- Small Cell Lung Cancer. J of IMAB. 2013 Jul-Dec;19(3):481-485. DOI: 10.5272/jimab.2013193.481.
Correspondence to: Dr Deyan Nikolov Davidov, Department of Chemotherapy, Oncological Center, Medical University; 1, “St. Kliment Ohridsky” Str., 5000 Pleven, Bulgaria; E-mail: dean_davidov@abv.bg;
REFERENCES:
1. Ho C, Davies AM, Lara PN Jr, Gandara DR. Second-line treatment for advanced-stage non-small- cell lung cancer: current and future options. Clin Lung Cancer. 2006 May;7 Suppl 4:S118-125. [PubMed]
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities of premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4): 212-236. [PubMed] [CrossRef]
3. Felip E, Rossel R. Pemetrexed as second- line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag. 2008 Jun;4(3):579- 85. [PubMed]
4. Russo F, Bearz A, Pampaloni G; Investigators of Italian Pemetrexed Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMCancer. 2008 Jul 31;8:216. [PubMed] [CrossRef]
5. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. [PubMed]
6. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006 Oct;130(4):1211-9. [PubMed] [CrossRef]
7. Non-small cell lung cancer collaborative group. Chemotherapy in nonsmall cell lung cancer: A meta- analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899- 909. [PubMed] [CrossRef]
8. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May;4(5):1087- 1100. [PubMed]
9. Shiller JH, Harington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non- small cell lung cancer. N Eng J Med. 2002 Jan 10;346(2):92- 98. [PubMed] [CrossRef]
10. Shih C, Chen VJ, Gossetti LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-1123. [PubMed]
11. Tonkinson JL, Wagner MM, Paul DC, Gates SG, Marder P, Mendelsohn LG et al. Cell cycle modulation by the multi-targeted anti-folate, LY231514, increases the antiproliferative activity of gemcitabine. Proc Am Assoc Cancer Res. 1996; 37:370.
12. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol. 20:76a, 2001 (abstr 300)
13. Calvert AH. Biochemical pharmacology of Pemetrexed. Oncology (Williston Park). 2004 Nov;18 (13 Suppl 8):13-17. [PubMed]
14. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Phamacol. 2003 Aug 1;66(3):431-438. [PubMed] [CrossRef]
15. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al., Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006 Oct 1;107(7):1589-1596. [PubMed] [CrossRef]
16. Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, et al. A phase I/II study of Pemetrexed and vinorelbine in patients with non- small cell lung cancer. Lung Cancer. 2005 Sep;49(3): 401-412. [PubMed] [CrossRef]
17. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is Pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of Pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer. 2007; 363 (Suppl): 6521.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207- 214. [PubMed]
19. Brimdage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst, 1993 Jul 21;85(14):1138-1148. [PubMed] [CrossRef]
20. Kaplan EL & Meter P. Nonparametric estimationfromincomplete observations. J Amer Statist Assn, 1958; 53:457- 481.
21. Shepherd FA. Chemotherapy for non- small cell lung cancer: have we reached a new plateau? Semin Oncol.1999 Feb;26(1 Suppl 4):3-11. [PubMed]
22. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus Pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-3551. [PubMed] [CrossRef]
23. Sigmond J, Backus H, Wouters D, Temmink O, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol. 2003 Aug 1;66(3):431-438. [PubMed] [CrossRef]
24. Giovannetti E, Mey V, Pasqualetti G, Marini l, Del Tacca M, Danesi R. Cellular and pharmacogenetics foundation of synergistic interaction of Pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-118. [PubMed] [CrossRef].
Accepted for publication: 11 October 2013
Published online: 21 December 2013